/GDRX
GDRX Stock - GoodRx Holdings, Inc.
Healthcare|Medical - Healthcare Information ServicesNASDAQ
$2.77+1.09%
+$0.03 (+1.09%) • Dec 19
57
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.1
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.61
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+26.4%upside
Target: $3.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GDRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.74 – $2.80
TARGET (TP)$3.50
STOP LOSS$2.55
RISK/REWARD1:3.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.47
52W High$5.81
52W Low$2.61
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $792.32M | $750.26M | $766.55M | $745.42M | $550.70M |
| Gross Profit | $744.11M | $683.34M | $701.48M | $698.71M | $521.11M |
| Gross Margin | 93.9% | 91.1% | 91.5% | 93.7% | 94.6% |
| Operating Income | $65.85M | $-27,007,000 | $1.74M | $13.41M | $-275,719,000 |
| Net Income | $16.39M | $-8,868,000 | $-32,828,000 | $-25,254,000 | $-293,623,000 |
| Net Margin | 2.1% | -1.2% | -4.3% | -3.4% | -53.3% |
| EPS | $0.04 | $-0.02 | $-0.08 | $-0.06 | $-1.07 |
Company Overview
GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was incorporated in 2015 and is headquartered in Santa Monica, California.
Visit WebsiteRating Distribution
Strong Buy
1
6%
Buy / Outperform
9
50%
Hold / Neutral
7
39%
Sell / Underperform
1
6%
Analyst Consensus🟡 Mixed
10 Bullish8 Neutral/Bearish
Price Targets
$10
Average Target
↑ 248.2% Upside
Now
$3
Low
$10
Average
$24
High
Based on 24 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2025 | Barclays | Initiation | Underweight | $3 |
| August 11th 2025 | Raymond James | Downgrade | Outperform | - |
| December 4th 2024 | Mizuho | Initiation | Neutral | $5 |
| August 9th 2024 | Raymond James | Upgrade | Strong Buy | $10 |
| May 23rd 2024 | RBC Capital Mkts | Upgrade | Outperform | $10← $8 |
| May 16th 2024 | Raymond James | Upgrade | Outperform | $10 |
| April 10th 2024 | KeyBanc Capital Markets | Upgrade | Overweight | $9 |
| March 25th 2024 | Wells Fargo | Upgrade | Overweight | $10← $7.5 |
| March 1st 2024 | JP Morgan | Upgrade | Overweight | $10← $7 |
| February 26th 2024 | Leerink Partners | Initiation | Outperform | $8 |
| January 2nd 2024 | BofA Securities | Downgrade | Underperform | $4.5← $8 |
| August 10th 2023 | DA Davidson | Upgrade | Buy | $9.5 |
| July 31st 2023 | TD Cowen | Upgrade | Outperform | $12← $6.5 |
| December 1st 2022 | Citigroup | Initiation | Buy | $7 |
| November 4th 2022 | JP Morgan | Upgrade | Neutral | $8← $10 |
Earnings History & Surprises
GDRXBeat Rate
39%
Last 18 quarters
Avg Surprise
+9.1%
EPS vs Estimate
Beats / Misses
7/7
4 met exactly
Latest EPS
$0.08
Q4 2025
EPS Surprise History
Q1 24
0.0%
$0.08vs$0.08
Q2 24
-11.1%
$0.08vs$0.09
Q3 24
-11.1%
$0.08vs$0.09
Q4 24
-11.1%
$0.08vs$0.09
Q1 25
-10.0%
$0.09vs$0.10
Q2 25
0.0%
$0.09vs$0.09
Q3 25
-10.0%
$0.09vs$0.10
Q4 25
-11.1%
$0.08vs$0.09
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $0.09 | — | — | — |
Q4 2025 | Nov 4, 2025 | $0.09 | $0.08 | -11.1% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $0.10 | $0.09 | -10.0% | ✗ MISS |
Q2 2025 | May 7, 2025 | $0.09 | $0.09 | 0.0% | = MET |
Q1 2025 | Feb 27, 2025 | $0.10 | $0.09 | -10.0% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $0.09 | $0.08 | -11.1% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $0.09 | $0.08 | -11.1% | ✗ MISS |
Q2 2024 | May 9, 2024 | $0.09 | $0.08 | -11.1% | ✗ MISS |
Q1 2024 | Feb 29, 2024 | $0.08 | $0.08 | 0.0% | = MET |
Q4 2023 | Nov 9, 2023 | $0.06 | $0.06 | 0.0% | = MET |
Q3 2023 | Aug 9, 2023 | $0.06 | $0.07 | +16.7% | ✓ BEAT |
Q2 2023 | May 10, 2023 | $0.06 | $0.07 | +16.7% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $0.05 | $0.07 | +40.0% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $0.04 | $0.07 | +72.6% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $0.04 | $0.06 | +54.4% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $0.08 | $0.10 | +25.0% | ✓ BEAT |
Q1 2022 | Feb 28, 2022 | $0.10 | $0.09 | -10.0% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $0.08 | $0.09 | +12.5% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $0.08 | $0.08 | 0.0% | = MET |
Latest News
Morgan Stanley Maintains Equal-Weight on GoodRx Holdings, Lowers Price Target to $4
➖ NeutralBenzinga•Dec 18, 2025, 05:56 PM
60 Degrees Pharma To Expand ARAKODA Sales And Marketing, Adding Reps, GoodRx Partnership And Enhanced Digital Campaign
📈 PositiveBenzinga•Dec 11, 2025, 01:19 PM
Barclays Initiates Coverage On GoodRx Holdings with Underweight Rating, Announces Price Target of $3
📉 NegativeBenzinga•Dec 9, 2025, 03:47 PM•Also:
GoodRx Launches $39 Per Month Weight Loss Telemedicine Subscription; Announces Introductory $199/Month Ozempic and Wegovy Pens
📈 PositiveBenzinga•Nov 17, 2025, 01:36 PM
JP Morgan Maintains Overweight on GoodRx Holdings, Lowers Price Target to $5
➖ NeutralBenzinga•Nov 11, 2025, 04:05 PM
TD Cowen Maintains Buy on GoodRx Holdings, Lowers Price Target to $6
➖ NeutralBenzinga•Nov 10, 2025, 05:30 PM
GoodRx Holdings shares are trading lower following a report suggesting that the company will not partner with TrumpRx.
📉 NegativeBenzinga•Nov 6, 2025, 07:45 PM
CBS Reporter Jennifer Jacobs Posts On X "News: Other drug websites such as GoodRx won't be partnering with TrumpRx, sources told me. One official cleared up misunderstandings about what TrumpRx will be, saying the federal govt website will send consumers to the pharmaceutical companies' websites, where they can purchase buy prescription drugs directly.
➖ NeutralBenzinga•Nov 6, 2025, 07:40 PM
UBS Maintains Neutral on GoodRx Holdings, Lowers Price Target to $4
➖ NeutralBenzinga•Nov 6, 2025, 06:36 PM
GoodRx Holdings FY2025 Revenue expected to be more than $792.300M vs $797.952M Est
📉 NegativeBenzinga•Nov 4, 2025, 09:13 PM
GoodRx Holdings Q3 Adj. EPS $0.08 Misses $0.09 Estimate, Sales $196.028M Beat $194.550M Estimate
➖ NeutralBenzinga•Nov 4, 2025, 09:13 PM
GoodRx Launches $16/Month Subscription For Hair Loss Treatment With Virtual Care And Home Delivery
📈 PositiveBenzinga•Oct 15, 2025, 03:19 PM
Hy-Vee Announces Through Its Partnership With GoodRx, All Strengths Of GLP-1 Medications Ozempic And Wegovy Pens Are Now Available Via GoodRx For $499-Per-Month
📈 PositiveBenzinga•Oct 10, 2025, 08:29 PM
GoodRx spikes after report on plans to join TrumpRx
📈 PositiveSeeking Alpha•Oct 9, 2025, 04:51 PM
GoodRx shares are trading higher after the company says its in talks with the Trump administration on TrumpRx participation.
📈 PositiveBenzinga•Oct 9, 2025, 04:44 PM
GoodRx Shares Resume Trade
➖ NeutralBenzinga•Oct 9, 2025, 04:34 PM
'Retail Pharmacies, GoodRx Say In Talks With Trump Administration On TrumpRx Participation' - Reuters Exclusive
📈 PositiveBenzinga•Oct 9, 2025, 04:25 PM
GoodRx Shares Halted On Circuit Breaker To The Upside, Stock Now Up 10.48%
📈 PositiveBenzinga•Oct 9, 2025, 04:24 PM
GoodRx And Amgen Partner To Offer Repatha Nationwide For $239
📈 PositiveBenzinga•Oct 6, 2025, 01:16 PM•Also:
Hims & Hers Health shares are trading lower after GoodRx announced a collaboration with Novo Nordisk to offer discounted GLP-1 medications.
📉 NegativeBenzinga•Aug 19, 2025, 07:07 PM•Also: ,
Frequently Asked Questions about GDRX
What is GDRX's current stock price?
GoodRx Holdings, Inc. (GDRX) is currently trading at $2.77 per share. The stock has moved +1.09% today.
What is the analyst price target for GDRX?
The average analyst price target for GDRX is $3.50, based on 1 analyst.
What sector is GoodRx Holdings, Inc. in?
GoodRx Holdings, Inc. operates in the Healthcare sector, specifically within the Medical - Healthcare Information Services industry. The company is traded on the NASDAQ exchange.
What is GDRX's market cap?
GoodRx Holdings, Inc. has a market capitalization of $0.94 billion, making it a small-cap company.
Does GDRX pay dividends?
No, GoodRx Holdings, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAHCO
AdaptHealth Corp.
$9.97
Mkt Cap: $1.4B
AMPH
Amphastar Pharmaceuticals, Inc.
$26.60
Mkt Cap: $1.2B
COLL
Collegium Pharmaceutical, Inc.
$48.88
Mkt Cap: $1.5B
CTEV
Claritev Corporation
$41.02
Mkt Cap: $0.7B
HSTM
HealthStream, Inc.
$23.94
Mkt Cap: $0.7B
INVA
Innoviva, Inc.
$19.99
Mkt Cap: $1.3B
IRMD
IRadimed Corporation
$97.19
Mkt Cap: $1.2B
LFMD
LifeMD, Inc.
$3.23
Mkt Cap: $0.2B
MDXG
MiMedx Group, Inc.
$7.05
Mkt Cap: $1.0B
PLSE
Pulse Biosciences, Inc.
$15.26
Mkt Cap: $1.0B
Explore stocks similar to GDRX for comparison